Patents by Inventor Stephan Roy

Stephan Roy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Smart media device platform as an inverse microscopic imaging apparatus
    Patent number: 10775600
    Abstract: An inverse microscope as a smart media device platform is provided. The smart media device platform includes a lower surface, sample stage, and a light source mount. The apparatus includes a lower, middle, and upper portion. The lower portion is a base that supports the smart media device, the middle portion is for the sample stage and the upper portion is the light source mount. The lower base is coupled to the middle sample stage by multiple support pillars. The inverse microscope further includes the magnifying loop as the objective, disposed proximal to the middle portion. And a light source disposed proximal to middle portion. The magnifying loop arm may be removed and replaced with a magnifying loop arm to achieve varied loop magnification power.
    Type: Grant
    Filed: December 30, 2018
    Date of Patent: September 15, 2020
    Inventor: Stephan Roy Mathis, II
  • SMART MEDIA DEVICE PLATFORM AS AN INVERSE MICROSCOPIC IMAGING APPARATUS
    Publication number: 20190204576
    Abstract: An inverse microscope as a smart media device platform is provided. The smart media device platform includes a lower surface, sample stage, and a light source mount. The apparatus includes a lower, middle, and upper portion. The lower portion is a base that supports the smart media device, the middle portion is for the sample stage and the upper portion is the light source mount. The lower base is coupled to the middle sample stage by multiple support pillars. The inverse microscope further includes the magnifying loop as the objective, disposed proximal to the middle portion. And a light source disposed proximal to middle portion. The magnifying loop arm may be removed and replaced with a magnifying loop arm to achieve varied loop magnification power.
    Type: Application
    Filed: December 30, 2018
    Publication date: July 4, 2019
    Inventor: Stephan Roy Mathis, II
  • Thiazolyl compounds useful as kinase inhibitors
    Patent number: 8343999
    Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I thiazolyl compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's disease.
    Type: Grant
    Filed: April 9, 2008
    Date of Patent: January 1, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Anne Marinier, Marco Dodier, Stephan Roy, Kurt Zimmermann, Xiaopeng Sang, Mark D. Wittman, David R. Langley, Ramkumar Rajamani
  • Thiazolyl compounds useful as kinase inhibitors
    Patent number: 8148400
    Abstract: The invention provides compounds of formula II: and pharmaceutically acceptable salts thereof. The formula II thiazolyl compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.
    Type: Grant
    Filed: December 19, 2007
    Date of Patent: April 3, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Anne Marinier, Claude A. Quesnelle, Marco Dodier, Stephan Roy, Patrice Gill, Mark D. Wittman, David R. Langley
  • THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS
    Publication number: 20100120770
    Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I thiazolyl compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's disease.
    Type: Application
    Filed: April 9, 2008
    Publication date: May 13, 2010
    Inventors: Anne Marinier, Marco Dodier, Stephan Roy, Kurt Zimmermann, Xiaopeng Sang, Mark D. Wittman, David R. Langley, Ramkumar Rajamani
  • THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS
    Publication number: 20100048581
    Abstract: The invention provides compounds of formula I [INSERT CHEMICAL STRUCTURE HERE] (I) and pharmaceutically acceptable salts thereof. The formula I thiazolyl compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.
    Type: Application
    Filed: December 19, 2007
    Publication date: February 25, 2010
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Anne Marinier, Claude A. Quesnelle, Marco Dodier, Stephan Roy, Patrice Gill, Mark D. Wittman, David R. Langley
  • Imidazole based kinase inhibitors
    Patent number: 7470713
    Abstract: The present invention provides compounds having formula I and their use for the treatment of cancer.
    Type: Grant
    Filed: February 18, 2005
    Date of Patent: December 30, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Anne Marinier, Stephan Roy, Alain Martel
  • Benzimidazole C-2 heterocycles as kinase inhibitors
    Patent number: 7312215
    Abstract: Benzimidazole derivatives having the general formula I are provided. These compounds are useful as tyrosine kinase inhibitors, especially for the treatment of cancer.
    Type: Grant
    Filed: July 20, 2004
    Date of Patent: December 25, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Francis Beaulieu, Anne Marinier, Carl Ouellet, Stephan Roy, Mark D. Wittman
  • Tyrosine kinase inhibitors
    Patent number: 7223757
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inhibiting tyrosine kinase enzymes.
    Type: Grant
    Filed: November 30, 2005
    Date of Patent: May 29, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark D. Wittman, Neelakantan Balasubramanian, Upender Velaparthi, Kurt Zimmermann, Mark G. Saulnier, Peiying Liu, Xiaopeng Sang, David B. Frennesson, Karen M. Stoffan, James G. Tarrant, Anne Marinier, Stephan Roy
  • Tyrosine kinase inhibitors
    Patent number: 7081454
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inhibiting tyrosine kinase enzymes.
    Type: Grant
    Filed: October 2, 2002
    Date of Patent: July 25, 2006
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Mark D. Wittman, Neelakantan Balasubramanian, Upender Velaparthi, Kurt Zimmermann, Mark G. Saulnier, Peiying Liu, Xiaopeng Sang, David B. Frennesson, Karen M. Stoffan, James G. Tarrant, Anne Marinier, Stephan Roy
  • Novel tyrosine kinase inhibitors
    Publication number: 20060079518
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inhibiting tyrosine kinase enzymes.
    Type: Application
    Filed: November 30, 2005
    Publication date: April 13, 2006
    Inventors: Mark Wittman, Neelakantan Balasubramanian, Upender Velaparthi, Kurt Zimmermann, Mark Saulnier, Peiying Liu, Xiaopeng Sang, David Frennesson, Karen Stoffan, James Tarrant, Anne Marinier, Stephan Roy
  • Imidazole based kinase inhibitors
    Publication number: 20050187218
    Abstract: The present invention provides compounds having Formula I and their use for the treatment of cancer.
    Type: Application
    Filed: February 18, 2005
    Publication date: August 25, 2005
    Inventors: Anne Marinier, Stephan Roy, Alain Martel
  • Thiophene-based tricyclic compounds and pharmaceutical compositions comprising same
    Patent number: 6933294
    Abstract: Compounds having the formula (I), and pharmaceutically-acceptable salts, hydrates and prodrugs thereof, are useful as anti-inflammatory agents, in which R1, R2, and R3 are hydrogen, halogen, alkyl, or perfluoroalkyl; R4 is an optionally substituted alkyl or cycloalkyl group; X is a linker; A is an aryl, heteroaryl, heterocycle, cycloalkyl, or is absent; and R7 is a substituent on A as defined in the specification.
    Type: Grant
    Filed: March 27, 2003
    Date of Patent: August 23, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Makonen Belema, Amy Bunker, Van Nguyen, Francis Beaulieu, Carl Ouellet, Anne Marinier, Stephan Roy, Xuejie Yang, Yuping Qiu, Yunhui Zhang, Alain Martel, Christopher Zusi
  • Benzimidazole C-2 heterocycles as kinase inhibitors
    Publication number: 20050054655
    Abstract: Benzimidazole derivatives having the general formula I are provided. These compounds are useful as tyrosine kinase inhibitors, especially for the treatment of cancer.
    Type: Application
    Filed: July 20, 2004
    Publication date: March 10, 2005
    Inventors: Francis Beaulieu, Anne Marinier, Carl Ouellet, Stephan Roy, Mark Wittman
  • Thiophene-based tricyclic compounds and pharmaceutical compositions comprising same
    Publication number: 20040058930
    Abstract: Compounds having the formula (I), 1
    Type: Application
    Filed: March 27, 2003
    Publication date: March 25, 2004
    Inventors: Makonen Belema, Amy Bunker, Van Nguyen, Francis Beaulieu, Carl Ouellet, Anne Marinier, Stephan Roy, Xuejie Yang, Yuping Qiu, Yunhui Zhang, Alain Martel, Christopher Zusi
  • Novel tyrosine kinase inhibitors
    Publication number: 20040044203
    Abstract: The present invention provides compounds of formula I 1
    Type: Application
    Filed: October 2, 2002
    Publication date: March 4, 2004
    Inventors: Mark D. Wittman, Neelakantan Balasubramanian, Upender Velaparthi, Kurt Zimmermann, Mark G. Saulnier, Peiying Liu, Xiaopeng Sang, David B. Frennesson, Karen M. Stoffan, James G. Tarrant, Anne Marinier, Stephan Roy
  • Alpha-and beta-substituted trifluoromethyl ketones as phospholipase inhibitors
    Patent number: 6414179
    Abstract: Inhibitors of the cytosolic phospholipase A2 enzymes are provided which are of use in controlling a wide variety of inflammatory diseases. The inhibitors of the present invention have the general formula where X, Z, R1, R2, R3, R4, Ra and Rb are as defined in the specification.
    Type: Grant
    Filed: March 23, 2001
    Date of Patent: July 2, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jacques Banville, Anne Marinier, Yonghua Gai, Serge Plamondon, Stephan Roy, Neelakantan Balasubramanian
  • Alpha-and beta- substituted trifluoromethyl ketones as phospholipase inhibitors
    Publication number: 20020065246
    Abstract: Inhibitors of the cytosolic phospholipase A2 enzymes are provided which are of use in controlling a wide variety of inflammatory diseases.
    Type: Application
    Filed: March 23, 2001
    Publication date: May 30, 2002
    Inventors: Jacques Banville, Anne Marinier, Yonghua Gai, Serge Plamondon, Stephan Roy, Neelakantan Balasubramanian